ร—

Ichor Life Sciences Acquires Woodland Biosciences, Inc.

This acquisition will allow Ichor's pharmacology division to engage in further specialized work.

Share







Two miceTwo mice

Woodland Biosciences, which studies metabolism and cancer, has joined the holdings of Ichor Life Sciences. Ichor intends to use Woodland’s expertise and research to increase the specializations of its pharmacological division. The full press release is provided here.

LaFayette, N.Y. โ€”ย Ichor Life Sciences, a premium preclinical contract research organization offering services in discovery through pharmacology, announces it has formally completed the acquisition of Woodland Biosciences, Inc. The in vivo services for the study of metabolic diseases and oncology provided by the former Woodland Biosciences are now available through Ichorโ€™s Pharmacology division.

A preclinical contract research organization, Woodland Biosciences was previously located on the campus of Tufts Veterinary Medicine School. Woodlandโ€™s R&D facilities have fully relocated from Tufts University to Ichorโ€™s facilities in LaFayette, New York. Dr. Michael Briggs, the President and CSO of Woodland Biosciences, continues as part of Ichorโ€™s scientific leadership in pharmacology. Dr. Briggs has deep expertise and experience in pharmacology and has worked on several preclinical and clinical programs in hepatitis, liver fibrosis and oncology, among others. Ichor Life Sciencesโ€™ clients and partners will continue to benefit from Dr. Briggsโ€™ involvement in study designs and insights that can progress their preclinical programs.

โ€œWoodland Biosciencesโ€™ capabilities in developing orthotopic and syngeneic models with a focus on liver and pancreatic cancers, along with models in NASH and other metabolic diseases, expands the specialization within our Ichor Pharmacology group,โ€ says Dr. Kelsey Moody, PhD, MBA, Ichor Life Sciencesโ€™ CEO. โ€œAs we seek to continuously add to our portfolio of services and broaden our expertise, we plan to identify other opportunities for acquisitions in the months ahead.โ€

With these acquisitions and Ichorโ€™s already deep expertise and capabilities in protein sciences and characterization, the company is well suited to provide a more comprehensive set of offerings from discovery through in vivo pharmacology to clients and partners in an innovative and entrepreneurial setting.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if itโ€™s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

Going to Wonderland with Microdose Psychedelic Insights

Microdose Psychedelic Insights, the leading guide to the business of psychedelics, is pleased to partner with Lifespan.io (Lifespan Extension Advocacy...

SENS Research Foundation Returns with Ending Aging Forum

It is not long before the SENS Research Foundation (SRF) hosts its second Ending Aging Forum! It will be happening...

AthenaDAO Launches Its $ATH Token

Mark your calendars: The opportunity to get in early and shape the most expansive and undertapped area of biotech is...

Singapore Opens Worldโ€™s First Healthy Longevity Clinic

The National University Health System, National University of Singapore and Alexandra Hospital have launched the worldโ€™s first Healthy Longevity Clinic...

No Comments
Write a comment:

*

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.